Drug intelligence / Profile preview

CKDB-101

Development stage: Preclinical
Lead developer: CKD Bio
Modality: Small Molecules

Overview

CKDB-101 is an investigational antibiotic candidate currently in the preclinical research and development (R&D) stage at CKD Bio. It is being developed for the treatment of bacterial infections. As part of CKD Bio's API (Active Pharmaceutical Ingredient) development pipeline, the drug likely leverages the company's expertise in fermentation and chemical synthesis. While it is explicitly categorized as an antibiotic in company documentation, specific details regarding its chemical class, molecular target, and spectrum of activity have not been publicly disclosed.

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on CKDB-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CKDB-101.

Explore the full profile